Femasys to Exhibit at the Annual AAGL 2024 Global Conference
November 07 2024 - 8:30AM
Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused
on addressing significant unmet needs of women worldwide with a
broad portfolio of in-office, accessible, and innovative
therapeutic and diagnostic products, announces that the Company
will be exhibiting at the American Association of Gynecologic
Laparoscopists (AAGL) 2024 Annual Global Conference, being held
November 16-19 in New Orleans, Louisiana. The Company will be
showcasing its product candidate in late-stage clinical
development, FemBloc®, as well as its other commercially available
solutions at booth #902.
About AAGL
AAGL is the largest medical society focused on
gynecologic surgery, with an international membership of over 7,500
physicians and healthcare providers committed to advancing
minimally invasive gynecologic surgery (MIGS). Its mission is to
elevate the quality and safety of health care for women through
excellence in clinical practice, education, research, innovation,
and advocacy. AAGL’s Annual Global Congress is the premier
scientific program that provides the world’s finest gynecologic
surgeons with the latest education and best practices in MIGS. To
learn more about AAGL 2024, visit the organization’s website.
About FemBloc
FemBloc® is a first-of-its-kind, nonsurgical, non-implant,
in-office solution in its late-stage of clinical development for
permanent birth control. It is intended to be a safer option for
women estimated at approximately half the cost of the long-standing
surgical alternative by eliminating the need for anesthesia,
incisions, and permanent implants. FemBloc has the potential to
offer women a convenient, accessible, and reliable option for those
seeking permanent birth control. For over 100 years there has been
stagnant innovation for permanent birth control which could lead to
a $20 billion market expansion opportunity for FemBloc in the U.S.
alone. For more information, visit www.FemBloc.com.
About Femasys
Femasys is a leading biomedical company focused on addressing
significant unmet needs of women worldwide with a broad portfolio
of in-office, accessible, and innovative therapeutic and diagnostic
solutions, including a lead revolutionary product candidate and
FDA-cleared products. FemaSeed® Intratubal Insemination, an
innovative infertility treatment designed to deliver sperm directly
where conception occurs, is FDA-cleared and has received regulatory
approval in Canada and Europe. FemBloc® permanent birth
control in late-stage clinical development is the first and only
non-surgical, in-office, permanent birth control method intended to
be a safer option for women at substantially less cost than the
long-standing surgical alternative. The Company has developed
diagnostic products that are complementary for which it has
achieved regulatory approvals to market in the U.S., Canada,
Europe, and other ex-U.S. territories, and which are
commercial-ready due to its in-house manufacturing capabilities.
Its diagnostic products include FemVue® and FemVue® Mini for
fallopian tube assessment by ultrasound, which can be used in
conjunction with FemCath®, an intrauterine catheter for selective
fallopian tube evaluation, and FemCerv®, an endocervical tissue
sampler for cervical cancer diagnosis. Learn more at
www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are
subject to substantial risks and uncertainties. Forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “pending,”
“intend,” “believe,” “suggests,” “potential,” “hope,” or “continue”
or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words.
Forward-looking statements are based on our current expectations
and are subject to inherent uncertainties, risks and assumptions,
many of which are beyond our control, difficult to predict and
could cause actual results to differ materially from what we
expect. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be
accurate. Factors that could cause actual results to differ
include, among others: our ability to develop and advance our
current product candidates and programs into, and successfully
initiate, enroll and complete, clinical trials; the ability of our
clinical trials to demonstrate safety and effectiveness of our
product candidates and other positive results; estimates regarding
the total addressable market for our products and product
candidates; our ability to commercialize our products and product
candidates, or the effect of delays in commercializing our
products, including FemaSeed; our business model and strategic
plans for our products, technologies and business, including our
implementation thereof; and those other risks and uncertainties
described in the section titled "Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 2023, and other
reports as filed with the SEC. Forward-looking statements contained
in this press release are made as of this date, and Femasys
undertakes no duty to update such information except as required
under applicable law.
Contacts:
Investors: Matt BlazeiIR@femasys.com
Media:Kati WaldenburgMedia@femasys.com
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Dec 2023 to Dec 2024